Skip to content
value.today

InCarda Therapeutics, Inc.

Formerly Pleiades Cardio-Therapeutics, Inc.

Total raised
$65 M
3 rounds on record
Latest round
$28 M
Oct 2020
First round on record
Mar 2017
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of InCarda Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2020$28 MNo. 3$10 to $50 million

InCarda Therapeutics, Inc.: Raise no. 3, Oct 2020

Investors in this round

5 investors had bought by the notice of Oct 21, 2020: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$28 M of $50 M offered; $22 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Grace Colon · Executive Officer, Director
  • Alan Colowick · Director
  • Andrew ElBardissi · Director
  • Dan Welch · Director
  • Isaac Cheng · Director
  • Johan Christenson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Grace Colon, CEO and President. Newest notice filed Oct 21, 2020. Read the notice at the SEC.

equity, optionsSEC
Oct 2017$35 MNo. 2$10 to $50 million

InCarda Therapeutics, Inc.: Raise no. 2, Oct 2017

Investors in this round

24 investors had bought by the notice of Nov 8, 2019: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $42 M offered; $7 M still to sell
Smallest investment taken
$1,791
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Grace Colon · Executive Officer, Director
  • Alan Colowick · Director
  • Andrew ElBardissi · Director
  • Bischofberger Norbert · Director
  • Dan Welch · Director
  • Isaac Cheng · Director
  • Johan Christenson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds to be used as working capital, including payment of director, officer and employee salaries.”

Signed by Grace Colon, CEO and President. Newest notice filed Nov 8, 2019. Read the notice at the SEC.

equitySEC
Mar 2017$2 MNo. 1$2 to $10 million

InCarda Therapeutics, Inc.: Raise no. 1, Mar 2017

Investors in this round

16 investors had bought by the notice of May 2, 2017: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $0 M still to sell
Smallest investment taken
$5,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Grace Colon · Executive Officer, Director
  • Miller Samantha · Executive Officer
  • Rangachari Narasimhan · Executive Officer, Director
  • Bischofberger Norbert · Director
  • McCarthy Reenie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds to be used as working capital, including payment of director, officer and employee salaries.”

Signed by Grace Colon, CEO and President. Newest notice filed May 2, 2017. Read the notice at the SEC.

debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • InCarda Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2020).

    SEC Form D · Oct 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2020

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of InCarda Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by InCarda Therapeutics, Inc.
NameRoleNamed in
Grace ColonExecutive officerOct 2020
Miller SamanthaExecutive officerMay 2017
Rangachari NarasimhanExecutive officerMay 2017
Alan ColowickDirectorOct 2020
Andrew ElBardissiDirectorOct 2020
Dan WelchDirectorOct 2020
Grace ColonDirectorOct 2020
Isaac ChengDirectorOct 2020
Johan ChristensonDirectorOct 2020
Bischofberger NorbertDirectorNov 2019
McCarthy ReenieDirectorMay 2017
Rangachari NarasimhanDirectorMay 2017